Clinical Trials Browser

Phase 1/2 × Neoplasms × Carmustine × Clear all

NCT03382977 2025-03-11

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1/2 Recruiting

Glioblastoma, Neoplasms